Cenegermin clinical trials
Also written Oxervate®.
How each study uses cenegermin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cenegermin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Aug 2018 · OXERVATE · BLA 761094 (FDA, Drugs@FDA)
- European Union
- 6 Jul 2017 · Oxervate · EMEA/H/C/004209 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Dompé Farmaceutici S.p.A (6) · Toyos Clinic (1) · Tufts Medical Center (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test cenegermin, phase 3 first.
- Sep 2027Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)Phase 3 · Dompé Farmaceutici S.p.A
Studies
Open first, then newest update. How each study uses cenegermin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)RecruitingPhase 3Dompé Farmaceutici S.p.ANCT07453888Written as Cenegermin
- An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCEDRecruitingPhase 3Dompé Farmaceutici S.p.ANCT07519902Written as Cenegermin
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye DiseaseCompletedPhase 3Dompé Farmaceutici S.p.ANCT05136170Written as Cenegermin
- Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic KeratitisCompletedPhase 4Dompé Farmaceutici S.p.ANCT04485546Written as cenegermin-bkbj
- DOMPE -MT Neurotrophic KeratitisActive, not recruitingPhase 4Toyos ClinicNCT06947850Written as Cenegermin Ophthalmic Solution [Oxervate]
- Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic KeratitisWithdrawnPhase 4Dompé Farmaceutici S.p.ANCT06411145Written as OXERVATE® 0.002%
- Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)CompletedPhase 3Dompé Farmaceutici S.p.ANCT05133180Written as Oxervate
- NGF Treatment for Patients With Neuropathic Corneal PainWithdrawnPhase 1Tufts Medical CenterNCT05700864Written as Cenegermin-Bkbj
As the comparator · 1 — what is tested is compared with cenegermin
Codes
What other systems call cenegermin · ClinicalTrials.gg INT001179
- MeSH (NLM) C000647429cenegerminConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) B6E7K36KT8CENEGERMINConfirmed FDA, NLM
- RxNorm 2104332One source FDA
- NCI Thesaurus C171893CenegerminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000647429 | cenegermin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | B6E7K36KT8 | CENEGERMIN | Confirmed FDA, NLM |
| RxNorm | 2104332 | — | One source FDA |
| NCI Thesaurus | C171893 | Cenegermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.